PORTFOLIO

Aclaris Therapeutics (NASDAQ: ACRS) is a specialty pharmaceutical company focused on the development of novel dermatological therapies.

Advanced Accelerator Applications (NASDAQ: AAAP) is pioneering the field of Molecular Nuclear Medicine and aims to provide predictive, preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients.

Agile Therapeutics (NASDAQ: AGRX) is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.

AirXpanders (ASX: AXP) is a medical device company that has developed the AeroForm tissue expander. AeroForm is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy.

Akari Therapeutics (NASDAQ: AKTX) is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.

Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

Ascendis Pharma (NASDAQ: ASND) develops differentiated prodrug versions of high-value drugs. The company’s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent lives.

Aurinia Pharmaceuticals is developing and delivering innovative products to patients suffering from debilitating diseases such as lupus nephritis (LN).

Biohaven Pharma (NASDAQ: BHVN) is a publicly held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.

BioPharmX (NYSE: BPMX) provides innovative healthcare products through its unique, patented platform technologies for pharmaceutical, over-the-counter (OTC), and supplement applications.

CRISPR Therapeutics is a world leader in CRISPR Cas9 gene editing technology.

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D.

Foamix (NASDAQ: FOMX) is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Impel NeuroPharma is using its Precision Olfactory Delivery (POD) nasal devices to develop therapies for diseases of the brain such as migraine and Alzheimer’s.

Kala is a company developing novel therapies to treat serious eye conditions.

KalVista Pharmaceuticals (NASDAQ: KALV) is creating a new generation of small molecule protease inhibitors.

Minerva Surgical is developing next-generation technology for treating excessive menstrual bleeding.

Nabriva (NASDAQ: NBRV) is an anti-infective company developing a novel therapy for Community Acquired Pneumonia.

Outpost Medicine is developing a novel therapy for overactive bladder and irritable bowel syndrome.

REGENXBIO (NASDAQ: RGNX) is a gene therapy platform company that is leveraging its proprietary NAV® Technology to advance the development of life-changing adeno-associated viral (AAV) treatments for lysosomal storage disorders, ocular diseases, and other unmet clinical needs.

Revance Therapeutics (NASDAQ: RVNC) is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology.

Selecta is a clinical-stage biopharmaceutical company advancing a pipeline of differentiated products designed to modulate the immune system.

Semnur Pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain.

SentreHEART is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications.

Sierra Oncology (NASDAQ: SRRA) is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

Soleno Therapeutics (NASDAQ: SLNO) is developing a novel treatment for patients with Prader-Willi syndrome (PWS).

Strongbridge Biopharma focuses on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions.

Surgical Specialties is a medical device company that is marketing surgical products on a worldwide basis.

Synapse BioMedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis.

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines.

Tricida, Inc. is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies.

Verona Pharma (LSE AIM:VRP.L) is focused on developing new drugs for a range of respiratory diseases.

Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide.